Rapidly growing well-differentiated cutaneous squamous cell carcinoma of the scalp in a patient who was immunosuppressed Authors: Kamila A Zub Carlsson, Øystein Sandanger, Lars Henrik Bjørneboe, Leif Roland Kørner, Kristin Halvorsen Hortemo Published: 2026 ABSTRACT AbstractA 74-year-old heart and kidney transplant recipient on long-term immunosuppressive drugs developed a rapidly enlarging well-differentiated cutaneous squamous cell carcinoma (cSCC) of the scalp. Delays related to multidisciplinary reassessment and intercurrent sepsis allowed for substantial tumour progression, ultimately precluding surgery and necessitating palliative radiotherapy. This case highlights that even well-differentiated cSCC may progress rapidly in patients who are immunosuppressed, underscoring the importance of timely treatment whenever feasible. Dear Editor, A 74-year-old man with multimorbidity who was taking long-term immunosuppressive drugs (prednisolone, ciclosporin and mycophenolate mofetil) after heart and kidney transplantations presented with a tumour of the left parietal scalp of 3 months’ duration (Figure 1a). He had previously undergone complete excision of a vertex cutaneous squamous cell carcinoma (cSCC) in situ with graft repair and no recurrence. Examination revealed a parietal 4 × 4-cm exophytic lesion with a cutaneous horn. Biopsies revealed a well-differentiated cSCC without perineural or vascular invasion (Figure 2), and imaging excluded calvarial invasion. The tumour was staged as a primary cT3N0M0 cSCC (American Joint Committee on Cancer 8th edition, stage III). Surgical resection was initially planned but was postponed owing to administrative delays related to multidisciplinary reassessment, as well as intercurrent sepsis. Three months later, the tumour had grown substantially (Figure 1b). It was decided that surgery was not advisable because of the tumour’s progression and the patient’s increasing frailty. Palliative radiotherapy achieved a partial response, but regrowth required repeated treatment 5 months later. Systemic therapy was considered unsuitable in this patient due to multimorbidity. While cemiplimab-based immunotherapy is a treatment option for inoperable cSCC and adjuvant therapy in high-risk disease, with potential application in the neoadjuvant setting, its use in transplant recipients warrants careful individualized assessment given the risk of allograft rejection.1 This case illustrates that, although well-differentiated cSCC typically grows slowly,2 rapid progression may occur in patients who are immunosuppressed,3 emphasizing the importance of timely treatment whenever feasible. (a) Initial presentation of a lobulated exophytic tumour with a cutaneous horn on the left parietal scalp, measuring 4 × 4 cm, 3 months after patient-reported onset. Histology showed well-differentiated cutaneous squamous cell carcinoma. (b) Follow-up image of the same lesion 3 months later, showing enlargement to 8 × 8 cm. Photomicrograph showing well-differentiated squamous cell carcinoma with infiltration of the dermis. The tumour features cells with abundant eosinophilic cytoplasm and some nuclear pleomorphism, as well as several mitoses (haematoxylin–phloxine–saffron stain, × 10 magnification). Contributor Information Kamila A Zub Carlsson, Department of Dermatology and Venereology, Oslo University Hospital, Oslo, Norway. Øystein Sandanger, Department of Dermatology and Venereology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Lars Henrik Bjørneboe, Department of Dermatology and Venereology, Oslo University Hospital, Oslo, Norway. Leif Roland Kørner, Department of Pathology, Akershus University Hospital, Oslo, Norway. Kristin Halvorsen Hortemo, Department of Dermatology and Venereology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Author contributions Kamila Anna Zub Carlsson (Concep­tualization, Data curation, Formal analysis, Methodology, Visualization [equal], Project administration, Writing—original draft, Writing—review & editing [lead]), Øystein Sandanger (Conceptualization, Formal analysis, Methodology, Writing—­original draft, Writing—review & editing [equal]), Lars Henrik Bjørneboe (Data curation, Validation, Writing—original draft, Writing—review & editing [equal]), Leif Roland Kørner (Data curation, Writing—review & editing [equal], Writing—original draft [supporting]), and Kristin Halvorsen Hortemo (Conceptualization, Data curation, Methodology, Project administration, Validation, Writing—original draft, Writing—review & editing [equal], Supervision [lead]). Funding sources This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. Conflicts of interest K.H.H. has received honoraria for lectures from AbbVie and SUN Pharma, and is a member of the project with partial financing from AbbVie and Sanofi. Ø.S. has received honorarium for lectures from Johnson&Johnson and is a member of a project with partial financing from Sanofi. K.A.Z.C. has received research grants from AbbVie and Sanofi. L.H.B. and L.R.K. declare no conflicts of interest. Data availability Data supporting the findings of this article are available from the corresponding author upon reasonable request. Ethics approval Not applicable. Patient consent Written informed consent was obtained from the patient for publication of clinical details and deidentified images. References Associated Data Data Availability Statement Data supporting the findings of this article are available from the corresponding author upon reasonable request.